JP2004531521A5 - - Google Patents

Download PDF

Info

Publication number
JP2004531521A5
JP2004531521A5 JP2002579985A JP2002579985A JP2004531521A5 JP 2004531521 A5 JP2004531521 A5 JP 2004531521A5 JP 2002579985 A JP2002579985 A JP 2002579985A JP 2002579985 A JP2002579985 A JP 2002579985A JP 2004531521 A5 JP2004531521 A5 JP 2004531521A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002579985A
Other languages
Japanese (ja)
Other versions
JP2004531521A (ja
JP4426761B2 (ja
Filing date
Publication date
Priority claimed from FR0104737A external-priority patent/FR2823222B1/fr
Application filed filed Critical
Publication of JP2004531521A publication Critical patent/JP2004531521A/ja
Publication of JP2004531521A5 publication Critical patent/JP2004531521A5/ja
Application granted granted Critical
Publication of JP4426761B2 publication Critical patent/JP4426761B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2002579985A 2001-04-06 2002-04-05 ウエストナイル熱ウイルスに対するワクチン Expired - Lifetime JP4426761B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0104737A FR2823222B1 (fr) 2001-04-06 2001-04-06 Vaccin contre le virus de la fievre du nil
PCT/FR2002/001200 WO2002081621A2 (fr) 2001-04-06 2002-04-05 Vaccin contre le virus de la fievre du nil

Publications (3)

Publication Number Publication Date
JP2004531521A JP2004531521A (ja) 2004-10-14
JP2004531521A5 true JP2004531521A5 (https=) 2005-07-28
JP4426761B2 JP4426761B2 (ja) 2010-03-03

Family

ID=8862055

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002579985A Expired - Lifetime JP4426761B2 (ja) 2001-04-06 2002-04-05 ウエストナイル熱ウイルスに対するワクチン

Country Status (21)

Country Link
EP (2) EP1377660B1 (https=)
JP (1) JP4426761B2 (https=)
AU (1) AU2002307971B2 (https=)
BE (1) BE2016C021I2 (https=)
BR (1) BRPI0208896B1 (https=)
CA (1) CA2448796C (https=)
CY (2) CY1117676T1 (https=)
DK (1) DK1377660T3 (https=)
ES (2) ES2767413T3 (https=)
FR (2) FR2823222B1 (https=)
HU (2) HU230122B1 (https=)
IL (3) IL158204A0 (https=)
LT (1) LTC1377660I2 (https=)
LU (1) LU93048I2 (https=)
MX (1) MXPA03008998A (https=)
NL (1) NL300806I2 (https=)
PL (2) PL210306B1 (https=)
RU (1) RU2283138C2 (https=)
SI (1) SI1377660T1 (https=)
WO (1) WO2002081621A2 (https=)
ZA (1) ZA200307620B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002232560A1 (en) 2000-10-27 2002-05-06 Immuno-Rx, Inc Vaccine immunotherapy for immune suppressed patients
HU228690B1 (en) 2001-07-27 2013-05-28 Wyeth Corp West nile vaccine
WO2004056977A1 (en) * 2002-12-13 2004-07-08 Aventis Pasteur, Inc. Production of alvac on avian embryonic stem cells
US8475808B2 (en) 2003-05-23 2013-07-02 Novartis Vaccines And Diagnostics, Inc. Immunogenic reagents from west nile virus
WO2006029300A2 (en) 2004-09-09 2006-03-16 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
PL2251034T3 (pl) 2005-12-02 2018-07-31 Icahn School Of Medicine At Mount Sinai Chimeryczne wirusy prezentujące nienatywne białka powierzchniowe i zastosowania tych wirusów
AU2009287449B2 (en) 2008-08-29 2015-04-30 Boehringer Ingelheim Animal Health USA Inc. West nile virus vaccine
EP2987856B1 (en) 2009-02-05 2018-07-25 Icahn School of Medicine at Mount Sinai Chimeric newcastle disease viruses and uses thereof
CN107375919B (zh) 2009-03-27 2022-07-29 台湾地区“中央研究院” 抗病毒免疫的方法和组合物
CA3017298C (en) * 2009-05-15 2021-09-28 Irx Therapeutics, Inc. Compositions comprising primary cell-derived biologics for enhancing immune responses in patients
TWI537385B (zh) 2010-11-04 2016-06-11 中央研究院 產生具簡單醣基化之表面蛋白質之病毒顆粒的方法
RU2506093C1 (ru) * 2012-12-06 2014-02-10 Государственное научное учреждение Якутский научно-исследовательский институт сельского хозяйства Российской академии сельскохозяйственных наук Способ специфической профилактики ринопневмонии, сальмонеллезного аборта и мыта лошадей ассоциированной вакциной в условиях табунного содержания
EP2968525A4 (en) 2013-03-14 2016-10-26 Icahn School Med Mount Sinai MORBUS NEWCASTLE VIRUSES AND USES THEREOF
EP3110443A4 (en) 2014-02-27 2017-11-15 Viralytics Limited Combination method for treatment of cancer
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
WO2021229270A1 (es) 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4963481A (en) 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
AU613316B2 (en) 1986-09-12 1991-08-01 Genentech Inc. Improved recombinant expression
DE3743138A1 (de) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg Schleifringlose, elektromagnetische ueberlastkupplung
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
DE69233158T2 (de) 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
US5382425A (en) 1992-01-13 1995-01-17 Syntro Corporation Recombinant swinepox virus
FR2702373B1 (fr) 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
EP0668355B1 (en) 1993-12-20 1999-04-07 Akzo Nobel N.V. Vaccine for the protection of horses against equine herpesvirus infection
FR2728794B1 (fr) 1994-12-30 1997-03-21 Rhone Merieux Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro
FR2728795B1 (fr) 1994-12-30 1997-03-21 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire
JPH11504631A (ja) 1995-04-25 1999-04-27 バイカル インコーポレイテッド Dna/脂質複合体の単一バイアル製剤
EP0979101B1 (en) 1996-07-03 2010-10-27 Merial, Inc. Recombinant canine adenovirus 2 (cav2) containing exogenous dna
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
FR2751225B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
FR2751226B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
EP0977587B1 (en) * 1997-02-28 2005-06-15 Acambis Inc. Chimeric flavivirus vaccines
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
US6294176B1 (en) 1998-07-10 2001-09-25 Schering-Plough Veterinary Corp. Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
US6416763B1 (en) * 1998-08-28 2002-07-09 Hawaii Biotechnology Group, Inc. Recombinant nonstructural protein subunit vaccine against flaviviral infection
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
CA2375320C (en) 1999-06-10 2013-02-19 Merial Dna vaccines for pets or for animals used in sports
FR2796397B1 (fr) 1999-07-16 2006-09-01 Merial Sas Genes de calicivirus felin et vaccins notamment vaccins recombines

Similar Documents

Publication Publication Date Title
BE2019C510I2 (https=)
BE2018C021I2 (https=)
BE2017C049I2 (https=)
BE2017C005I2 (https=)
BE2016C069I2 (https=)
BE2016C040I2 (https=)
BE2015C078I2 (https=)
BE2016C002I2 (https=)
BE2018C018I2 (https=)
BE2015C017I2 (https=)
BE2014C053I2 (https=)
BE2014C051I2 (https=)
BE2014C041I2 (https=)
BE2014C030I2 (https=)
BE2014C016I2 (https=)
BE2014C015I2 (https=)
BE2013C063I2 (https=)
BE2013C039I2 (https=)
BE2011C038I2 (https=)
BE2015C067I2 (https=)
BE2013C046I2 (https=)
JP2003009461A5 (https=)
JP2004531521A5 (https=)
HU0201980D0 (https=)
AU2001278584A1 (https=)